Big Buttons

• FDA doubles down: Tirzepatide is off shortage

  ...but that doesn't mean the issue is completely settled. read more →

• A couple of state updates

  Good news from Alabama, but a problem in Massachusetts read more →

• Defending GLP-1 compounding

  The latest letters APC's been sending to oppose efforts to restrict compounding read more →

• Thumbs-up for FDA crackdown

  APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →

• A PANS/PANDAS explainer

  For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →

• What, a year?

  In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →

• “Simply not a rational approach to regulating an industry”

  This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →

• Get a cease and desist letter from Verrica?

  APC has heard reports from several pharmacies that have received them — here's what to know. read more →

More News

We’ve been busy this week on the state regulatory front, submitting comments on bills in Illinois and Maryland and sending our new statement on peptide compounding to all state boards of pharmacy. Here’s the lowdown:

• ​​Illinois HB 5517 would require both 503A compounding pharmacies and 503B outsourcing facilities to register as a pharmaceutical marketing firm and provide a list of all employees who are sales representatives. Our comments assert that the bill is an invasion of privacy, imposes an unnecessary hardship to pharmacies and outsourcing facilities, and will not decrease the cost of medications dispensed by pharmacies or outsourcing facilities.
• Maryland HB 1099 was intended to allow veterinarians and veterinary technicians to compound medications, but the bill has now been withdrawn. APC’s comments outline the numerous conflicts with compounding regulations and best practices that the bill language presented.
• We also sent a memo to all 50 state boards of pharmacy sharing our newly published public statement “Understanding Law and Regulation Governing the Compounding of Peptide Products.” The goal in sharing the statement is to provide accurate information for board members, investigators, and licensees.